VELCADE Drug Patent Profile

When do Velcade patents expire, and when can generic versions of Velcade launch?

Velcade is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in VELCADE is bortezomib. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the bortezomib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Velcade

A generic version of VELCADE was approved as bortezomib by APOTEX on May 2^nd, 2022.

Summary for VELCADE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	600
Patent Applications:	196
Drug Prices:	Drug price information for VELCADE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VELCADE
What excipients (inactive ingredients) are in VELCADE?	VELCADE excipients list
DailyMed Link:	VELCADE at DailyMed

See drug prices for VELCADE

Recent Clinical Trials for VELCADE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	PHASE4
Stichting European Myeloma Network	Phase 2
KKS Netzwerk	Phase 3

See all VELCADE clinical trials

Pharmacology for VELCADE

Drug Class	Proteasome Inhibitor
Mechanism of Action	Proteasome Inhibitors

Paragraph IV (Patent) Challenges for VELCADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VELCADE	For Injection	bortezomib	3.5 mg/vial	021602	1	2008-11-20

US Patents and Regulatory Information for VELCADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	AP	RX	Yes	Yes

Expired US Patents for VELCADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,747,150
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,083,903
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,617,317

EU/EMA Drug Approvals for VELCADE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Bortezomib Accord	bortezomib	EMEA/H/C/003984Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	yes	no	no	2015-07-20
Pfizer Europe MA EEIG	Bortezomib Hospira	bortezomib	EMEA/H/C/004207Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	yes	no	no	2016-07-22
SUN Pharmaceutical Industries (Europe) B.V.	Bortezomib Sun	bortezomib	EMEA/H/C/004076Bortezomib SUN as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	yes	no	no	2016-07-22

International Patents for VELCADE

See the table below for patents covering VELCADE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	241631
Austria	314378
Austria	411324

Supplementary Protection Certificates for VELCADE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0788360	91083	Luxembourg		91083, EXPIRES: 20190426
0788360	300151	Netherlands		300151, 20151027, EXPIRES: 20190425
0788360	CA 2004 00012	Denmark

Last updated: June 22, 2026

VELCADE (bortezomib) market dynamics and financial trajectory: pricing, demand drivers, competition, and exclusivity-to-loss-of-sales path

Executive summary: VELCADE (bortezomib) is a legacy multiple myeloma proteasome inhibitor with declining long-term revenue from sustained competitive pressure by newer oral proteasome inhibitors (carfilzomib, ixazomib), CD38/BCMA-directed regimens, and combination standard-of-care shifts. The drug’s financial trajectory has been driven by (1) decreasing share of frontline and relapsed multiple myeloma, (2) continued use in settings where rapid disease control and subcutaneous dosing matter, and (3) IP and regulatory transitions that enabled generic and biosimilar-like substitutes for key formulations in multiple geographies. In the US, VELCADE’s original US exclusivity base ended years ago; the business now depends on life-cycle management (formulation, dosing route) and negotiated access, not on patent runway.

---

What drives VELCADE (bortezomib) market dynamics in multiple myeloma: frontline vs relapsed mix?

VELCADE’s commercial demand is tied to the cadence of multiple myeloma treatment lines and regimen selection.

Primary demand drivers

• Clinical role in relapsed/refractory multiple myeloma (RRMM): Bortezomib-based regimens remain used where clinicians prioritize fast response, proteasome inhibition, and combination frameworks.
• Subcutaneous administration adoption: Subcutaneous dosing improved tolerability versus IV for peripheral neuropathy risk management, supporting persistence in some formularies where uptake is clinically justified.
• Combination compatibility: Bortezomib historically anchors multiple regimen combinations (with dexamethasone and immunomodulatory agents like lenalidomide or with monoclonal antibodies), though regimen preferences shift as newer backbones gain uptake.
• Patient access and payer contracting: As new agents become preferred, VELCADE demand becomes more sensitive to payer reimbursement and formulary positioning.

Primary demand headwinds

• Regimen substitution by proteasome inhibitor evolution: Oral proteasome inhibitor ixazomib and IV second-generation proteasome inhibitor carfilzomib have taken share in portions of the market, reducing bortezomib exposure.
• Immunotherapy-led standard changes: CD38 monoclonal antibodies and BCMA-targeted therapies change the relative value proposition across earlier lines and post-exposure sequences.
• Neuropathy and tolerability constraints: Even with subcutaneous dosing, peripheral neuropathy limits dosing intensity and drives switching, especially among frail or neuropathy-prone patients.
• Price compression and channel changes: As exclusivity ended and market competition intensified, net pricing pressure reduced revenue resilience.

Market implication

• VELCADE behaves like a high-utilization legacy oncology drug: sales tend to track overall myeloma volume but shrink as newer combinations displace it at the margin.

---

How has VELCADE’s pricing and net revenue trended versus newer myeloma standards?

VELCADE’s financial trajectory is consistent with legacy oncology patterns: peak pricing supported by exclusivity, followed by net revenue decline as competitive alternatives and formulary preferences increased.

What typically matters in bortezomib net pricing

• US payer rebates and contracting: As generics entered and competitors gained positioning, net price fell faster than list price.
• Geographic procurement differences: In export markets and ex-US regions, pricing is sensitive to local generic competition and reimbursement policies.
• Mix shift from IV to subcutaneous: Subcutaneous dosing can help offset decline by sustaining clinician preference, but it does not reverse displacement from newer backbones.

Financial mechanics

• Net revenue decline is usually faster than volume decline because of rebate and competitive pricing.
• The drug’s revenue base tends to fall in cycles that follow major guideline shifts and label expansions of newer regimens.

---

When does VELCADE lose exclusivity and how did patent expiry reshape the revenue curve?

VELCADE’s major revenue inflection points occurred when core protection ended and generic entrants expanded.

US exclusivity and IP dynamics (high level)

• VELCADE’s original development period pre-dates today’s myeloma standard landscape, so the drug has already passed the long exclusivity windows available for new molecular entities and has faced generic competition.
• Life-cycle protection for specific formulations and administration routes is limited relative to the overall molecule, so post-expiry revenue depends on substitution speed rather than long residual exclusivity.

Typical downstream effect on revenue

• Post-patent erosion: rapid share loss in the most accessible markets.
• Slower erosion in constrained lines: in practice settings where clinicians choose bortezomib for speed-of-response and where subcutaneous tolerability still fits patient needs.

---

What generic entry risks exist for VELCADE: Paragraph IV challenges and market substitute pathways?

Generic penetration for legacy small molecules like bortezomib tends to occur through:

• ANDA approvals for the active ingredient and permitted formulations (subject to label and manufacturing controls).
• Route and formulation substitutions where permitted (IV vs SC considerations).

Market substitute pathways

• Generic bortezomib (small-molecule generic substitution): the primary commercial substitute is a direct generic equivalent where approved.
• Therapeutic substitutes (not generics): carfilzomib, ixazomib, and combinations built around CD38 or BCMA therapies reduce bortezomib’s clinical addressable share.

Commercial takeaway

• The competitive risk to VELCADE is twofold: direct generic substitution and therapeutic displacement by new regimens. The second risk often drives the most meaningful long-term share decline even after generic availability.

---

What is the Orange Book status of VELCADE and how does that map to expected competitive intensity?

In the Orange Book framework, VELCADE’s position would typically be characterized by:

• Listings for bortezomib drug products across strengths and dosage forms (IV and SC).
• Patent expirations already largely completed for foundational protections.
• Residual listings for formulation or method-of-use may persist longer, but they rarely prevent substitution when core drug product protections lapse and generic ANDAs are approved.

Market mapping

• When Orange Book listings no longer provide enforceable protection, expected outcomes are:
  • increased generic supply,
  • rebate-driven net pricing pressure,
  • incremental share loss to generics and therapeutic alternatives.

(Note: No Orange Book dataset was provided in the prompt, so specific listing counts, patent numbers, and listed expiration dates cannot be stated here.)

---

How strong is the patent estate for bortezomib (VELCADE): method-of-use vs formulation coverage?

For legacy oncology drugs, “remaining strength” typically lives in:

• formulation patents (device delivery, dosing route specifics, stability, or excipient systems),
• process/method patents (manufacturing steps),
• method-of-use patents (specific combinations, sequences, or patient subsets).

However, for market outcomes

• Even when method-of-use patents persist, practical clinical use is influenced by:
  • guideline consensus,
  • payer policies,
  • labeling alignment,
  • clinician treatment selection.

Commercial consequence

• If method-of-use protections are narrow or not consistently asserted, they may not stop generic substitution and may not stop therapeutic displacement.

(Note: Patent-number-level strength scoring requires a concrete list of granted Orange Book and related patents; none was supplied.)

---

What VELCADE formulations are protected and how do dosage route and administration affect competitive behavior?

VELCADE has commercial relevance in both IV and subcutaneous dosing, with subcutaneous often preferred to manage neuropathy.

Dosage route effects

• Subcutaneous positioning: can maintain demand and adherence when prescribers perceive lower neuropathy burden and improved convenience.
• IV sensitivity: IV usage patterns depend on infusion center logistics and patient-specific tolerability.

Competitive effect

• Even where substitution is approved for the same route, manufacturing and handling requirements, and local supply availability can determine speed of uptake.

---

Which companies are challenging VELCADE and what litigation typically follows legacy generic entry?

Generic entry campaigns for legacy small molecules usually trigger:

• Hatch-Waxman Paragraph IV litigation between the brand holder and ANDA filers (or successor holders).
• Settlement agreements that set “carve-out” or launch triggers based on patent expiry dates, design-around changes, or exclusivity periods (if any).

What matters commercially

• The presence of multiple ANDA filers increases pressure on net pricing even when early launches are delayed.
• If settlements produce earlier “at-risk” launch windows, the revenue impact comes in a step-function rather than a smooth decline.

(Note: The prompt does not provide a litigation docket, patent numbers, or settlement terms.)

---

How does VELCADE’s financial trajectory compare with ixazomib and carfilzomib in multiple myeloma?

Therapy-to-therapy displacement framework

• Ixazomib: oral administration supports convenience and can shift use from injected bortezomib in suitable patients, compressing bortezomib addressable share.
• Carfilzomib: second-generation proteasome inhibitor with different efficacy and tolerability profile can displace bortezomib in lines where cardiac or renal profiles are acceptable.

Relative commercial posture (typical for the class)

• Older, injected proteasome inhibition loses share as regimens move toward:
  • oral chronic administration (ixazomib),
  • high-efficacy proteasome options (carfilzomib),
  • combination-led immunotherapy and BCMA-directed sequences.

Net effect on VELCADE revenue

• Even with stable baseline demand in RRMM, the long-term trend usually tracks:
  • declining frontline and early relapsed use,
  • higher share of later-line use where newer regimens are not tolerable or available,
  • discounting after generic entry.

---

What regulatory pathways and label events have most influenced VELCADE demand?

For oncology legacy products, demand shifts often follow:

• label expansions for combination regimens that increase eligible populations,
• route or dosing refinements that reduce treatment-limiting toxicities,
• safety communications that influence clinician behavior.

Demand impact pattern

• Label changes that improve tolerability can temporarily stabilize volume.
• Safety or toxicity concerns can accelerate switching to alternative backbones.

(Note: No label-event timeline was provided.)

---

What does VELCADE’s commercialization strategy look like after exclusivity: lifecycle, contracting, and contracting leverage?

Post-exclusivity strategy for a legacy oncology brand typically centers on:

• formulary retention through negotiated pricing,
• support for subcutaneous administration and patient workflow advantages,
• targeting niche patient populations where bortezomib is clinically preferred.

Commercial leverage

• When therapeutic substitutes are available, brand leverage relies more on:
  • total regimen cost,
  • toxicity management outcomes,
  • payer outcomes evidence,
  • and supply reliability.

Financial trajectory implication

• Revenue stabilizes only if net pricing is protected and substitution is slowed by clinical practice patterns.
• Over time, therapeutic displacement compresses the “remaining loyal” patient base.

---

Key Takeaways

• VELCADE’s market dynamics are dominated by therapeutic displacement (ixazomib, carfilzomib, CD38 and BCMA-based regimens) and price compression after generic competition.
• The financial trajectory aligns with legacy small-molecule oncology behavior: post-exclusivity revenue erosion that can be partially offset by subcutaneous tolerability advantages and formulary contracting.
• Competitive pressure operates on two fronts: direct generic equivalents and alternative standards of care that reduce bortezomib’s clinical addressable share.
• Long-term performance depends less on patent runway and more on payer access, remaining line-of-therapy usage, and tolerability-driven clinician choice.

---

FAQs

1) Why do clinicians still use VELCADE in relapsed multiple myeloma despite newer proteasome inhibitors?
Because bortezomib regimens can still offer rapid disease control and fit certain combination strategies, with subcutaneous dosing supporting neuropathy risk management in practice.

2) What substitutions hurt VELCADE the most: generic bortezomib or newer therapies?
In most markets, the most durable pressure is therapeutic displacement by newer myeloma backbones and immunotherapy-led regimens, while generics drive pricing compression.

3) Does subcutaneous dosing materially change VELCADE’s competitive position?
It can support formulary and clinician preference by improving tolerability relative to IV, but it does not prevent overall share erosion from regimen shifts.

4) How does multiple myeloma line-of-therapy sequencing affect VELCADE revenue?
If bortezomib’s role shrinks in earlier lines, its sales generally decline even if later-line volume remains steady.

5) What commercial events most accelerate revenue declines for legacy oncology drugs like VELCADE?
Generic launch events that reduce net pricing, plus guideline or payer preference changes that move standard-of-care combinations away from bortezomib.

---

References

No sources were provided in the prompt, and no drug-specific patent, Orange Book, litigation, or financial dataset was supplied to support citation-grade assertions.